Novo Nordisk flags board members for re-election amid restructuring efforts
In a bid to regain operational stability, Novo Nordisk’s Board of Directors has nominated two new members to join the committee, which has…
23 Feb 2026
AstraZeneca’s Calquence plus venetoclax gains approval in US to treat CLL
AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma…
23 Feb 2026
Roche receives FDA acceptance for giredestrant combo NDA
Roche has obtained acceptance from the US Food and Drug Administration (FDA) for its new drug application (NDA) submitted for giredestrant, an oral therapy, along with everolimus to treat breast…
20 Feb 2026
Ex-Trump official-ran Altesa secures $75m in Series B funding round
Altesa BioSciences has closed an oversubscribed $75m Series B funding round to advance the clinical development of its antiviral, vapendavir. With funding from lead investor Forbion, as well as contributions…
20 Feb 2026
WHO wants improved universal vaccines to win global influenza battle
The World Health Organization (WHO) has outlined the benefits that improved influenza vaccines could offer, as the agency seeks to overcome a more hesitant vaccine development sector in the US.…
20 Feb 2026
Boehringer Ingelheim and NIPER sign MoU on pharmaceutical research
Boehringer Ingelheim India has signed a memorandum of understanding (MoU) to enhance pharmaceutical education and research collaboration. The MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli,…
20 Feb 2026
Syngene and VivaMed collaborate on therapeutic programmes
Syngene International has entered a strategic collaboration with VivaMed BioPharma to advance AI-derived repurposed therapeutic programmes. This partnership aims to broaden VivaMed’s validation infrastructure for AI-driven drug repurposing partnership programmes…